Engineered Polymeric Micelles for Combinational Oxidation

Biomacromolecules , 2019, 20 (2), pp 1109–1117. DOI: 10.1021/acs.biomac.8b01802. Publication Date (Web): January 3, 2019. Copyright © 2019 American...
1 downloads 0 Views 3MB Size
Subscriber access provided by University of Kansas Libraries

Article

Engineered polymeric micelles for combinational oxidation anticancer therapy through concurrent HO-1 inhibition and ROS generation Joungyoun Noh, Eunkyeong Jung, Jeonghun Lee, Hyejin Hyun, Seri Hong, and Dongwon Lee Biomacromolecules, Just Accepted Manuscript • Publication Date (Web): 03 Jan 2019 Downloaded from http://pubs.acs.org on January 3, 2019

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

Engineered polymeric micelles for combinational oxidation anticancer therapy through concurrent HO-1 inhibition and ROS generation Joungyoun Noh a, Eunkyeong Jung b, Jeonghun Lee b, Hyejin Hyun b, Seri Hong b, Dongwon Lee a,b,*

a Department

of PolymerNano Science and Technology, Chonbuk National University,

Baekjedaero 567, Jeonju, Chonbuk, 54896, Republic of Korea

b Department

of BIN Convergence Technology, Chonbuk National University, Baekjedaero

567, Jeonju, Chonbuk, 54896, Republic of Korea

Corresponding Author

ACS Paragon Plus Environment

Biomacromolecules 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

*E-mail: [email protected],

ABSTRACT

Cancer cells have a large amount of ROS (reactive oxygen species) because of disturbed ROS homeostasis. Cancer cells therefore undertake redox adaptation to drive proliferation in tumor environments and even survive during anticancer treatment by upregulating endogenous antioxidants. As one of antioxidant defense systems, heme oxygenase-1 (HO-1) acts as essential roles in tumor development by offering antioxidant bilirubin to protect cancer cells under stress conditions. It can be therefore reasoned that the combination of ROS generation and HO-1 inhibition would exert synergistic anticancer effects through the amplification of oxidative stress and provide a new opportunity for targeted anticancer therapy. To establish targeted anticancer therapy based on amplified oxidative stress, we developed molecularly engineered polymer, termed CZP, which incorporates ROS generating CA (cinnamaldehyde) and HO-1 inhibiting ZnPP (zinc protoporphyrin) in

ACS Paragon Plus Environment

Page 2 of 38

Page 3 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

its backbone and could form stable micelles in aqueous solutions. CZP micelles not only elevated oxidative stress but also suppressed the expression of antioxidant HO-1, leading to apoptotic cell death. CZP micelles could also significantly suppress the tumor growth without body weight loss, tumor recurrence and noticeable toxicity in organs. This study demonstrates that combination of ROS generation and HO-1inhibition synergistically magnifies oxidative stress to kill cancer cells and oxidative stress amplifying CZP micelles may provide a promising strategy in anticancer treatment.

Keywords: oxidative stress; oxidation anticancer therapy; cancer; micelles; heme oxygenase-1 1. Introduction In spite of substantial improvement in the drug discovery, molecular biology and oncology over the past decade, cancer is as one of the major causes of death worldwide as ever.1-3 One of the straightforward and powerful approaches for cancer treatment is chemotherapy using various

ACS Paragon Plus Environment

Biomacromolecules 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

anticancer drugs, but most anticancer drugs have some limitations for instance, deficient bioavailability, lack of target specificity, the possibility to induce multidrug resistance and adverse side effects.2,4 To get over these shortcomings, extensive efforts have been dedicated to developing effective anticancer therapeutic strategy. “Oxidation therapy” is one of the recently developed anticancer therapies and has gained increasing attractions.5-7 Oxidation therapy exploits the redox imbalance in cancer cells. In comparison with normal cells, cancer cells have an elevated level of ROS such as singlet oxygen, hydrogen peroxide and hydroxyl radicals and therefore are under oxidative stress.7-8 Although the intracellular level of ROS in cancer cells are not exactly determined, almost all cancer cells are known to have excessive ROS such as prostate cancer cells and colorectal cancer cells.9-11 Cancer cells are hence more easily affected by therapeutic agents including arsenic trioxide (As2O3), cisplatin, glucose oxidase and cinnamaldehyde that stimulate ROS generation to kill cancer cells preferentially.5,12-13 On the other hand, quinone methide (QM), -phenylethyl isocyanate and buthionone sulfoximine were reported to deplete antioxidant defense systems and exacerbate the redox imbalance in cancer cells, giving rise to cell death.14-18 One of promising and powerful approaches to maximize oxidative stress in anticancer treatment would be the combination of ROS generation and antioxidant depletion.6,12,15,19 Concurrent delivery of ROS generators and antioxidant inhibitors to cancer cells could drastically amplify the oxidative stress to kill cancer cells and could be referred to as “combinational oxidation anticancer therapy”. Various combinations of ROS-generating compounds and antioxidant-inhibiting compounds could be made to achieve synergistic effects in the amplification of oxidative stress, targeting selective destruction of cancer cells.4,15 In this work, cinnamaldehyde (CA) and zinc

ACS Paragon Plus Environment

Page 4 of 38

Page 5 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

protoporphyrin (ZnPP) were selected as a ROS-generating compound and antioxidant-inhibiting agent, respectively. CA is a major ingredient in cinnamon which has been extensively used in foods including beverage, ice cream and candies and herbal medicine.20-21 Accumulative evidence has demonstrated that CA and its derivatives trigger apoptosis of cancer cells through mitochondrial membrane disruption and caspase activation.22-24 On the other hand, ZnPP is known to elevate oxidative stress by depleting antioxidant heme oxygenase-1 (HO-1), which is a heme degrading enzyme. HO-1 is present at low concentration under normal conditions, but plays a vital role in tumor development by protecting cancer cells under stress conditions such as heat shock, hypoxia, high-energy radiation, ROS and heavy metals.15,25-26 It has been reported that cancer cells exploit the cytoprotective functions of HO-1 as a shield from chemo- and radiotherapy. Moreover, Maeda et al. have recently reported that ZnPP exerts potent anticancer activity by inhibiting HO-1 and also moderates the therapeutic responses of cancer cells to ROS generating anticancer drugs.27-28 Although a number of researchers have documented the therapeutic potential of CA and ZnPP in cancer treatment, it is necessary to develop methodologies to deliver CA and ZnPP concurrently to targeted cancer cells to maximize synergistic therapeutic effects and overcome their intrinsic limitations such as poor solubility, low bioavailability and lack of targetability.15,29-33 One of the promising strategies to address these challenges encountered in combinational oxidation anticancer therapy would be the covalent incorporation of both ROS generators and antioxidant inhibitors in the chain of stimulus-responsive biodegradable polymer.30,34 This strategy could realize the concurrent delivery of both therapeutic agents and high drug loading capacity and also enhance their bioavailability. On the basis of great therapeutic potential of CA and ZnPP and

ACS Paragon Plus Environment

Biomacromolecules 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

the advantages of polymeric prodrugs, we developed CZP (CA and ZnPP-incorporated polymer) as a combinational oxidation anticancer therapeutic agent.

Scheme 1. A schematic diagram showing the construction of CZP micelles with their working mechanism of combinational oxidation anticancer therapy.

As illustrated in Scheme 1, CA is incorporated covalently in the poly(-amino ester) through the formation of acid-sensitive acetal linkages. ZnPP is also grafted to side chains of the polymer. CZP could form thermodynamically stable micelles through self-assembly in aqueous environments and be activated by acidic pH in cancer microenvironments to

ACS Paragon Plus Environment

Page 6 of 38

Page 7 of 38 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Biomacromolecules

liberate CA and ZnPP. Therefore, the hypothesis behind the therapeutic actions of CZP micelles is that ZnPP-mediated inhibition of antioxidant HO-1 renders cancer cells highly vulnerable to CA-mediated ROS insults and therefore the elevated oxidative stress could induce preferential cancer cell death. In addition, CZP micelles with a mean diameter of